Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Gene Therapy Drug May Show Promise In Treatment Of Huntington’s Disease

XTALKS VITALS NEWS

Wal-Mart

A novel gene therapy drug developed by antibody company Vybion, has been shown to block cellular gene dysregulation and delay cognitive and motor problems associated with Huntington’s disease.

Tweetables from this article:

Tweet: The drug candidate is currently in late-stage preclinical development for the treatment of Huntington’s disease http://ctt.ec/d9KhBThe drug candidate is currently in late-stage preclinical development for the treatment of Huntington’s disease.

Share this!

September 1, 2016 | by Sarah Massey, M.Sc.

A novel gene therapy drug developed by antibody company Vybion has been shown to block cellular gene dysregulation and delay cognitive and motor problems associated with Huntington’s disease. The details of the intrabody drug INT41, an antibody that binds to an intracellular protein, were published in the Journal of Neurodegenerative Diseases.

INT41 prevents toxic N-terminal huntingtin fragments from being transported into the nucleus of the cell and blocks them from binding with the DNA. The drug was tested in the well-validated R6/2 mouse model of Huntington’s disease.

“We believe that our therapeutic approach to the treatment of Huntington's disease has provided a biological rationale linking Huntington's disease progression and toxic N-terminal fragments,” said Dr. Lee Henderson, CEO of Vybion. “We look forward to completing our plans for human patient trials.”

The drug candidate is currently in late-stage preclinical development for the treatment of Huntington’s disease. Vybion’s proprietary technologies revolve around the discovery and development of intrabody drugs for multiple neurodegenerative diseases.

“The data also demonstrate that Vybion's platform may have broader application in generating intrabody drug candidates to difficult-to-drug targets, including intracellular proteins in neurodegenerative disorders and other disease areas such as oncology,” said a statement released by Vybion. “Further, the platform may be used to validate new targets of interest, particularly in intracellular signal transduction pathways, prior to generation of new therapeutic candidates.”


Keywords: Gene Therapy, Huntington's Disease, Drug Development


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Insurance Coverage Under the Affordable Care Act Supports Clinical Trial Enrollment, Says Study

July 20, 2017 - Since the Patient Protection and Affordable Care Act (ACA) was passed in 2010, insurance approval for patients wishing to participate in oncology clinical trials has increased, according to a recent study published in the journal, Clinical Cancer Research.

Featured In: Clinical Trial News


FDA Approves Puma Biotechnology’s Extended Adjuvant Therapy for Breast

July 19, 2017 - Puma Biotechnology’s breast cancer drug Nerlynx (neratinib) has been approved by the US Food and Drug Administration (FDA).

Featured In: Biotech News


CAR-T Cell Therapy Shows Promise as Leukemia Treatment in Early Stage Clinical Trial

July 19, 2017 - About 70 percent of clinical trial participants with chronic lymphocytic leukemia experienced tumor shrinkage after being treated with CAR-T immunotherapy, according to researchers at Fred Hutchinson Cancer Research Center.

Featured In: Clinical Trial News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know

REGISTER FOR THESE WEBINARS

Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned


EDC and eSource: Combined for Better Data and Faster Insights


Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide


How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology


Copyright © 2016-2017 Honeycomb Worldwide Inc.